Your session is about to expire
← Back to Search
Deep Brain Stimulation
Deep Brain Stimulation for Obsessive-Compulsive Disorder
N/A
Waitlist Available
Led By Darin D Dougherty, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age between 21 and 65 years
Be older than 18 years old
Must not have
Pregnancy and women of childbearing age not using effective contraception
Any current clinically significant neurological disorder or medical illness affecting brain function, other than tic disorders or Tourette syndrome
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial uses a device that sends electrical signals to the brain to help patients with severe OCD who haven't responded to other treatments. It works by correcting abnormal brain activity and also records data to help researchers understand the treatment better. Deep brain stimulation (DBS) is an innovative treatment for severe obsessive-compulsive disorder (OCD).
Who is the study for?
Adults aged 21-65 with severe OCD, not improved after multiple treatments including drugs and behavioral therapy, can join this trial. They must be in good health, understand the study, consent to it, have a supportive family member or friend, and live near the study site. Excluded are those with psychotic disorders, low IQ/cognitive impairments affecting consent ability, bipolar disorder history, MRI contraindications like metal implants or claustrophobia.
What is being tested?
The Medtronic PC+S deep brain stimulation device is being tested as a treatment for patients with intractable OCD. This involves surgical implantation of electrodes into specific brain areas to modulate activity through electrical impulses.
What are the potential side effects?
Potential side effects may include discomfort at the implant site, headache following surgery or stimulation adjustments; risk of infection; possible changes in mood or behavior; and rarely bleeding inside the brain.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am between 21 and 65 years old.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I am not pregnant and if of childbearing age, I use effective contraception.
Select...
I do not have any brain-affecting illnesses except for tic disorders or Tourette syndrome.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Yale-Brown Obsessive-Compulsive Scale (YBOCS)
Secondary study objectives
Clinical Global Impressions (CGI) Severity and Change scale
Montgomery-Asberg Depression Rating Scale (MADRS)
Patient Global Impressions (PGI) scale
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Medtronic Percept Deep Brain StimulationExperimental Treatment1 Intervention
Single open label arm.
Patients with severe, treatment-refractory obsessive-compulsive disorder (OCD) will receive stimulation in two separate, but related, brain regions, the dorsolateral prefrontal cortex (dlPFC) and the ventral anterior limb of the internal capsule and adjacent ventral striatum (VC/VS) with a novel Medtronic Percept deep brain stimulation (DBS) system.
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Obsessive-Compulsive Disorder (OCD) include pharmacological therapies like selective serotonin reuptake inhibitors (SSRIs) and neuromodulation therapies such as Deep Brain Stimulation (DBS). SSRIs work by increasing serotonin levels in the brain, which helps alleviate OCD symptoms.
DBS involves the implantation of electrodes that deliver electrical impulses to specific brain areas to regulate abnormal activity. This is crucial for patients with treatment-resistant OCD, providing an alternative when conventional treatments are ineffective.
Find a Location
Who is running the clinical trial?
Massachusetts General HospitalLead Sponsor
3,026 Previous Clinical Trials
13,413,787 Total Patients Enrolled
26 Trials studying Obsessive-Compulsive Disorder
1,619 Patients Enrolled for Obsessive-Compulsive Disorder
Darin D Dougherty, MDPrincipal InvestigatorMassachusetts General Hospital
5 Previous Clinical Trials
110 Total Patients Enrolled
4 Trials studying Obsessive-Compulsive Disorder
50 Patients Enrolled for Obsessive-Compulsive Disorder
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am between 21 and 65 years old.I am not pregnant and if of childbearing age, I use effective contraception.I am in good health overall.I have not changed my medications in the last 6 weeks.I cannot have an MRI due to a pacemaker, metal in my body, pregnancy, or severe claustrophobia.I do not have any brain-affecting illnesses except for tic disorders or Tourette syndrome.I've had severe symptoms for 5+ years despite trying multiple treatments.I have not changed my medications in the last 6 weeks.I've had severe symptoms for 5+ years despite trying multiple treatments.I am between 21 and 65 years old.I can understand and sign the consent form.I have severe OCD with a YBOCS score of 28 or more.
Research Study Groups:
This trial has the following groups:- Group 1: Medtronic Percept Deep Brain Stimulation
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.